http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105603115-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
| filingDate | 2016-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105603115-B |
| titleOfInvention | Lung squamous cancer shifts diagnosis and treatment marker |
| abstract | The invention discloses miR-3923 judge lung squamous cancer whether occur shift or prejudge lung squamous cancer shift risk in application.MiR-3923 can be used to develop accordingly the drug for inhibiting lung squamous cancer transfer, invasion or the transfer of prevention lung squamous cancer, invasion.Research achievement of the invention provides fundamental basis for clinician's formulation personalized therapy program and can provide new drug target for the exploitation of lung squamous cancer transfer invasion drug. |
| priorityDate | 2016-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 21.